262 related articles for article (PubMed ID: 23173040)
1. Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.
Zhuang J; Zhang J; Lwin ST; Edwards JR; Edwards CM; Mundy GR; Yang X
PLoS One; 2012; 7(11):e48871. PubMed ID: 23173040
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cells contribute to bone erosion in collagen-induced arthritis by differentiating to osteoclasts.
Zhang H; Huang Y; Wang S; Fu R; Guo C; Wang H; Zhao J; Gaskin F; Chen J; Yang N; Fu SM
J Autoimmun; 2015 Dec; 65():82-9. PubMed ID: 26318644
[TBL] [Abstract][Full Text] [Related]
3. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
Görgün GT; Whitehill G; Anderson JL; Hideshima T; Maguire C; Laubach J; Raje N; Munshi NC; Richardson PG; Anderson KC
Blood; 2013 Apr; 121(15):2975-87. PubMed ID: 23321256
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cell-derived osteoclasts with bone resorption capacity in the joints of arthritic SKG mice.
Fujikawa Y; Sendo S; Del Peral Fanjul A; Yamada H; Uto K; Yamamoto Y; Nagamoto T; Morinobu A; Saegusa J
Front Immunol; 2024; 15():1168323. PubMed ID: 38566990
[TBL] [Abstract][Full Text] [Related]
5. Age-related expansion and increased osteoclastogenic potential of myeloid-derived suppressor cells.
Li Z; Zhao Y; Chen Z; Katz J; Michalek SM; Li Y; Zhang P
Mol Immunol; 2021 Sep; 137():187-200. PubMed ID: 34274794
[TBL] [Abstract][Full Text] [Related]
6. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.
Li X; Liao J; Park SI; Koh AJ; Sadler WD; Pienta KJ; Rosol TJ; McCauley LK
Bone; 2011 Jun; 48(6):1354-61. PubMed ID: 21419883
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.
Porembka MR; Mitchem JB; Belt BA; Hsieh CS; Lee HM; Herndon J; Gillanders WE; Linehan DC; Goedegebuure P
Cancer Immunol Immunother; 2012 Sep; 61(9):1373-85. PubMed ID: 22215137
[TBL] [Abstract][Full Text] [Related]
8. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cells expand during breast cancer progression and promote tumor-induced bone destruction.
Danilin S; Merkel AR; Johnson JR; Johnson RW; Edwards JR; Sterling JA
Oncoimmunology; 2012 Dec; 1(9):1484-1494. PubMed ID: 23264895
[TBL] [Abstract][Full Text] [Related]
10. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
Hirbe AC; Roelofs AJ; Floyd DH; Deng H; Becker SN; Lanigan LG; Apicelli AJ; Xu Z; Prior JL; Eagleton MC; Piwnica-Worms D; Rogers MJ; Weilbaecher K
Bone; 2009 May; 44(5):908-16. PubMed ID: 19442620
[TBL] [Abstract][Full Text] [Related]
11. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity.
Michigami T; Shimizu N; Williams PJ; Niewolna M; Dallas SL; Mundy GR; Yoneda T
Blood; 2000 Sep; 96(5):1953-60. PubMed ID: 10961900
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.
Kimachi K; Kajiya H; Nakayama S; Ikebe T; Okabe K
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):297-308. PubMed ID: 21225243
[TBL] [Abstract][Full Text] [Related]
13. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
[TBL] [Abstract][Full Text] [Related]
14. Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma.
Binsfeld M; Muller J; Lamour V; De Veirman K; De Raeve H; Bellahcène A; Van Valckenborgh E; Baron F; Beguin Y; Caers J; Heusschen R
Oncotarget; 2016 Jun; 7(25):37931-37943. PubMed ID: 27177328
[TBL] [Abstract][Full Text] [Related]
15. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
[TBL] [Abstract][Full Text] [Related]
16. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
17. Effect of Advanced Oxidation Protein Products (AOPPs) and aging on the osteoclast differentiation of Myeloid-Derived Suppressor Cells (MDSCs) and its preliminary mechanism.
Zou L; Jiang W; Wang Z; Chen J; Zhu S
Biochem Biophys Res Commun; 2022 Dec; 636(Pt 2):87-96. PubMed ID: 36368159
[TBL] [Abstract][Full Text] [Related]
18. Expansion of myeloid-derived suppressor cells contributes to metabolic osteoarthritis through subchondral bone remodeling.
Zhang L; Kirkwood CL; Sohn J; Lau A; Bayers-Thering M; Bali SK; Rachala S; Marzo JM; Anders MJ; Beier F; Kirkwood KL
Arthritis Res Ther; 2021 Nov; 23(1):287. PubMed ID: 34784965
[TBL] [Abstract][Full Text] [Related]
19. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
Edwards CM; Mueller G; Roelofs AJ; Chantry A; Perry M; Russell RG; Van Camp B; Guyon-Gellin Y; Niesor EJ; Bentzen CL; Vanderkerken K; Croucher PI
Int J Cancer; 2007 Apr; 120(8):1657-63. PubMed ID: 17230522
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function.
Charles JF; Hsu LY; Niemi EC; Weiss A; Aliprantis AO; Nakamura MC
J Clin Invest; 2012 Dec; 122(12):4592-605. PubMed ID: 23114597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
